Common · Knowledge
Aflibercept
Pharmaceutical drug
Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals. It is an inhibitor of vascular endothelial growth factor (VEGF).
From Wikipedia
Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals. It is an inhibitor of vascular endothelial growth factor (VEGF). Aflibercept is a recombinant fusion protein consisting of the extracellular domains of human VEGF receptor 1 and 2 fused to the Fc portion of human IgG1. By acting as a soluble decoy for the natural VEGF receptors, aflibercept inhibits their activation, thereby reducing angiogenesis.
Text: Wikipédia, CC BY-SA 4.0. · Image: Sławomir Liberski, Małgorzata Wichrowska, Jarosław Kocięcki;... (Public domain) ·
Related cards
-
★
Faricimab
Experimental monoclonal antibody
-
A★
Angiogenesis inhibitor
Agent and endogenous substance that antagonizes or inhibits the development of new blood vessels
-
★★
Fluorometholone
Chemical compound
-
★
Cetuximab
Pharmaceutical drug
-
★★★
Dapagliflozin
Chemical compound
-
★
Trametinib
Chemical compound